ReviewJournal of clinical medicine2022
Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Predictive Value of Neutrophil-to-Lymphocyte Ratio for Immune Checkpoint Inhibitor-Related Myocarditis Among Patients Treated for Non-Small-Cell Lung Cancer.Cancer innovation · 2025Article
- Tumor-Activated Neutrophils Promote Lung Cancer Progression through the IL-8/PD-L1 Pathway.Current cancer drug targets · 2025Article
- The causal role of immune cells on lung cancer: a bi-directional Mendelian randomization (MR) study.Aging · 2024Article
- Unveiling the Influence of AI Predictive Analytics on Patient Outcomes: A Comprehensive Narrative Review.Cureus · 2024Review
- Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma.Scientific reports · 2024Article
- Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023.Frontiers in immunology · 2024Article
- Plasmacytoid Dendritic Cell, SlanCancers · 2023Article
- Article
- Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy.Biomolecules · 2023Observational
- Article
- Advanced Research on Immune Checkpoint Inhibitor Therapy.Journal of clinical medicine · 2022Article
- Article
- Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer.International journal of molecular sciences · 2022Article
- Advances in artificial intelligence to predict cancer immunotherapy efficacy.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have dramatically improved the outcomes of non-small cell lung cancer patients and have increased the possibility of long-term survival. However, few patients benefit from ICIs, and no predictive biomarkers other than tumor programmed cell death ligand 1 (PD-L1) expression have been established. Hence, the identification of biomarkers is an urgent issue. This review outlines the current understanding of predictive markers for the efficacy of ICIs, including PD-L1, tumor mutation burden, DNA mismatch repair deficiency, microsatellite instability, CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.